Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy